RxDoctor Payments Data

Holly Chwastowski

Primary Care · Independence, OHNPI 1760153530

Payments from drug & device makers

$1,306in general payments, 2019–2025

Across 28 payments — averaging $46.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$338
  • Boston Scientific$183
  • Astellas Pharma US Inc$182
  • Teleflex LLC$159
  • Antares Pharma, Inc.$131
  • Sumitomo Pharma America, Inc.$123
  • plus $191 from 5 others

What the payments were for

  • Food & beverage$1,306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,306 in reported general payments places this provider in the 75th percentile of 321 primary care providers in Ohio.

See all primary care providers in Ohio

Medicare billing

Part B allowed, 2024
$32,408
Medicare patients
169
Services billed
2,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron146$121,212
EliquisApixaban19$18,090
Tamsulosin Hcl476$6,035
Testosterone28$4,205
Solifenacin Succinate50$3,947
Trospium Chloride62$3,145
Methenamine Hippurate32$3,133
Finasteride264$2,906
Desmopressin Acetate13$2,687
Fesoterodine Fumarate ErFesoterodine Fumarate22$2,282
Potassium Citrate ErPotassium Citrate19$1,887
Testosterone Cypionate29$1,521
Oxybutynin Chloride ErOxybutynin Chloride50$1,466
Alfuzosin Hcl ErAlfuzosin Hcl46$851
Estradiol13$720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$182$121,212146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 321 primary care providers in Ohio.

Other primary care in Independence

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →